This company has been marked as potentially delisted and may not be actively trading. Cogent Biosciences (UMRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock UMRX vs. PCRX, HROW, SYRE, WVE, AUPH, OPK, ELVN, RCUS, MLYS, and AKBAShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Pacira BioSciences (PCRX), Harrow (HROW), Spyre Therapeutics (SYRE), Wave Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), OPKO Health (OPK), Enliven Therapeutics (ELVN), Arcus Biosciences (RCUS), Mineralys Therapeutics (MLYS), and Akebia Therapeutics (AKBA). These companies are all part of the "medical" sector. Cogent Biosciences vs. Its Competitors Pacira BioSciences Harrow Spyre Therapeutics Wave Life Sciences Aurinia Pharmaceuticals OPKO Health Enliven Therapeutics Arcus Biosciences Mineralys Therapeutics Akebia Therapeutics Cogent Biosciences (NASDAQ:UMRX) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk. Is UMRX or PCRX more profitable? Pacira BioSciences has a net margin of -13.07% compared to Cogent Biosciences' net margin of -96.84%. Pacira BioSciences' return on equity of 13.42% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent Biosciences-96.84% -87.78% -52.14% Pacira BioSciences -13.07%13.42%7.19% Do insiders & institutionals believe in UMRX or PCRX? 26.4% of Cogent Biosciences shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 31.5% of Cogent Biosciences shares are owned by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media favor UMRX or PCRX? In the previous week, Pacira BioSciences had 8 more articles in the media than Cogent Biosciences. MarketBeat recorded 8 mentions for Pacira BioSciences and 0 mentions for Cogent Biosciences. Pacira BioSciences' average media sentiment score of 1.36 beat Cogent Biosciences' score of 0.00 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Overall Sentiment Cogent Biosciences Neutral Pacira BioSciences Positive Does the MarketBeat Community favor UMRX or PCRX? Pacira BioSciences received 646 more outperform votes than Cogent Biosciences when rated by MarketBeat users. Likewise, 71.60% of users gave Pacira BioSciences an outperform vote while only 68.38% of users gave Cogent Biosciences an outperform vote. CompanyUnderperformOutperformCogent BiosciencesOutperform Votes18668.38% Underperform Votes8631.62% Pacira BioSciencesOutperform Votes83271.60% Underperform Votes33028.40% Do analysts rate UMRX or PCRX? Pacira BioSciences has a consensus target price of $26.44, suggesting a potential upside of 9.09%. Given Pacira BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Pacira BioSciences is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Pacira BioSciences 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has stronger earnings and valuation, UMRX or PCRX? Pacira BioSciences has higher revenue and earnings than Cogent Biosciences. Pacira BioSciences is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent Biosciences$22.50M13.36-$31.83M-$1.04-6.81Pacira BioSciences$702.77M1.60$41.96M-$2.28-10.63 Which has more volatility and risk, UMRX or PCRX? Cogent Biosciences has a beta of 3.93, meaning that its stock price is 293% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. SummaryPacira BioSciences beats Cogent Biosciences on 13 of the 18 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UMRX vs. The Competition Export to ExcelMetricCogent BiosciencesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$300.68M$6.87B$5.57B$8.50BDividend YieldN/A2.52%5.28%4.16%P/E Ratio-9.328.4326.6319.64Price / Sales13.36262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book6.816.536.964.60Net Income-$31.83M$143.25M$3.23B$248.06M Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UMRXCogent BiosciencesN/A$7.08-1.9%N/A-20.1%$300.68M$22.50M-9.3272Gap DownPCRXPacira BioSciences2.4611 of 5 stars$24.87-2.2%$26.44+6.3%-14.6%$1.15B$702.77M-12.25720Positive NewsHROWHarrow2.3619 of 5 stars$31.17+3.4%$61.25+96.5%+69.0%$1.14B$212.86M-33.16182News CoveragePositive NewsAnalyst ForecastAnalyst RevisionGap UpSYRESpyre Therapeutics2.4117 of 5 stars$18.56+8.2%$53.40+187.7%-46.6%$1.12B$890K-2.4873Positive NewsGap DownWVEWave Life Sciences4.2505 of 5 stars$7.23+2.6%$21.17+192.8%+7.3%$1.11B$104.94M-6.51240News CoverageAnalyst ForecastInsider TradeAnalyst RevisionGap DownAUPHAurinia Pharmaceuticals3.288 of 5 stars$8.15+0.1%$11.50+41.1%+52.9%$1.10B$247.30M-54.33300Positive NewsAnalyst RevisionOPKOPKO Health4.4718 of 5 stars$1.38flat$2.75+99.3%+3.9%$1.09B$689.41M-7.264,200ELVNEnliven Therapeutics2.5058 of 5 stars$21.70+6.7%$37.25+71.7%-0.5%$1.06BN/A-11.4250News CoverageInsider TradeGap DownHigh Trading VolumeRCUSArcus Biosciences2.3041 of 5 stars$10.04+1.9%$24.13+140.4%-45.6%$1.06B$141M-3.19500Options VolumeAnalyst RevisionGap UpMLYSMineralys Therapeutics2.7967 of 5 stars$16.03-1.0%$38.00+137.1%+12.8%$1.04BN/A-4.4028Analyst ForecastGap DownAKBAAkebia Therapeutics4.0121 of 5 stars$3.92+2.3%$6.75+72.2%+217.9%$1.03B$184.91M-17.04430High Trading Volume Related Companies and Tools Related Companies PCRX Alternatives HROW Alternatives SYRE Alternatives WVE Alternatives AUPH Alternatives OPK Alternatives ELVN Alternatives RCUS Alternatives MLYS Alternatives AKBA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UMRX) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
